High-throughput screening for Kv1.3 channel blockers using an improved FLIPR-based membrane-potential assay.
Liu, Kun; Samuel, Manoj; Tillett, Jeff; Hennan, James K; Mekonnen, Belew; Soloveva, Veronica; Harrison, Richard K; Paslay, Jeff W; Larocque, James.
J Biomol Screen
; 15(2): 185-95, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20044579
Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life.
Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant.
Identification of novel Kv1.3 blockers using a fluorescent cell-based ion channel assay.
Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone.
Pharmacological inhibition of Kv1.3 fails to modulate insulin sensitivity in diabetic mice or human insulin-sensitive tissues.
T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers.
Autocrine-Based Selection of Drugs That Target Ion Channels from Combinatorial Venom Peptide Libraries.
[Effect of Kv1.3 and KCa3.1 potassium ion channels on the proliferation and migration of monocytes/macrophages].
A novel current pathway parallel to the central pore in a mutant voltage-gated potassium channel.
Endogenous animal toxin-like human ß-defensin 2 inhibits own K(+) channels through interaction with channel extracellular pore region.